Heading off depressive illness evolution and progression to treatment resistance
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Viewing recurrent depression as a potentially progressive illness may help transform treatment toward earlier, more consistent intervention and prevention. Evidence indicates that recurrent stressors, episodes of depression, and bouts of substance abuse can each show sensitization (increased reactivity upon repetition) and cross-sensitization to the others, and drive illness progression and treatment resistance. These long-lasting increases in pathological responsivity appear to be mediated by epigenetic mechanisms involving alterations in chemical marks placed on DNA and histories. These types of sensitization effects are amenable to clinical attempts at amelioration and prevention, and provide treatment targets and strategies to minimize the likelihood of illness progression to treatment resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allostasis and Allostatic Load Implications for Neuropsychopharmacology
McEwen, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00129-3 · Cited by 1,833
Lasting epigenetic influence of early-life adversity on the BDNF gene
Roth, T. L., Lubin, F. D., Funk, A. J., & Sweatt, J. D. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.028 · Cited by 1,273
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Kendler, K. S., Thornton, L. M., & Gardner, C. O. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1243 · Cited by 721
Mehta, D., Klengel, T., Conneely, K. N., Smith, A. K., Altmann, A., Pace, T. W., Rex-Haffner, M., Loeschner, A., Gonik, M., Mercer, K. B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217750110 · Cited by 548
Families at High and Low Risk for Depression: A 3-Generation Study
Weissman, M. M., Wickramaratne, P., Nomura, Y., Warner, V., Verdeli, H., Pilowsky, D. J., Grillon, C., & Bruder, G. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.29 · Cited by 500
Kendler, K. S., Thornton, L. M., & Gardner, C. O. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.582 · Cited by 480
Severe Mental Illness and Risk of Cardiovascular Disease
Newcomer, J. W., & Hennekens, C. H. (2007) · JAMA · doi:10.1001/jama.298.15.1794 · Cited by 433
Wolkowitz, O. M., Mellon, S. H., Epel, E. S., Lin, J., Dhabhar, F. S., Su, Y., Reus, V. I., Rosser, R., Burke, H. M., Kupferman, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017837 · Cited by 421
Cited by
Adjibade, M., Julia, C., Allès, B., Touvier, M., Lemogne, C., Srour, B., Hercberg, S., Galan, P., Assmann, K. E., & Kesse-Guyot, E. (2019) · BMC Medicine · doi:10.1186/s12916-019-1312-y · Cited by 227
Balmus, I. M., Ciobica, A., Antioch, I., Dobrin, R., & Timofte, D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3975101 · Cited by 103
“Also, other antioxidant and anxiolytic agents have been proven to be effective against the oxidative stress status such as epigallocatechin gallate (EGCG), green tea polyphenol [184], and chlorogenic acid, a dietary polyphenol [185], as we will insist in the last chapter of this minireview dedicated to the relevance o…”
BackgroundOrmel (2019) · doi:10.1097/yco.0000000000000505 · Cited by 102
“Evidence indicates that recurrent episodes of depression, stressors, and spells of substance abuse can show sensitization (increased reactivity upon repetition) and cross-sensitization to the others, and drive illness progression and treatment resistance [43,71].”
Lifetime duration of depressive disorders in patients with type 2 diabetes
de Groot, M., Crick, K. A., Long, M., Saha, C., & Shubrook, J. H. (2016) · Diabetes Care · doi:10.2337/dc16-1145 · Cited by 54
Staging of depressive disorders: Relevance of resistance to treatment and residual symptoms
Reneses, B., Aguera-Ortiz, L., Sevilla-Llewellyn-Jones, J., Carrillo, A., Argudo, I., Regatero, M. J., López-Micó, C., Fuentes, M., & Palomo, T. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.07.022 · Cited by 7
Metadata
- Authors
- Post, R. M.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2015-06-30
- Volume
- 17
- Issue
- 2
- Pages
- 105-109
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- OpenAlex
- W2346575005
- Cited by
- 16
- References
- 15
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heading off depressive illness evolution and progression to treatment resistance. https://app.cochat.ai/papers/10.31887/dcns.2015.17.2/rpost
- The paper
- Post, R. M. (2015). Heading off depressive illness evolution and progression to treatment resistance. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2015.17.2/rpost
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.